China’s drug regulator clears mpox vaccine; to undergo clinical trial
Beijing, Sep 10: China’s top drug regulator has cleared a mpox vaccine developed by local drug firm Sinopharm for clinical trials which could be the country’s first experimental dose to battle the deadly disease.
The domestic vaccine candidate, created by the Shanghai Institute of Biological Products and administered by Sinopharm, is expected to play an important role in preventing and controlling mpox infections, the company said in a statement released on Monday afternoon.
There is currently no approved mpox vaccine in China. Globally, a few vaccines have been approved in the United States, Canada, the European Union, Japan and Russia.
In China, a vaccine candidate typically goes through three phases of clinical trials before gaining market approval.
The process can take years, even decades. However, the National Medical Products Administration, China's top drug regulator, has launched a number of accelerated or streamlined channels to facilitate applications of novel drugs and vaccines or those in urgent need, state-run China Daily reported on Tuesday.
According to the company, the new vaccine is a replication-deficient vaccine based on a strain called MVA.
The description is the same as Jynneos, the world's first mpox vaccine approved by the Food and Drug Administration in the United States in 2019.
The World Health Organisation said on August 14 that the mpox outbreak in Africa constitutes a public health emergency of international concern — its highest form of alert.
Previously, in July 2022, the WHO declared a global emergency but then lifted it in May last year because of a sustained decline in international cases.
So far, more than 120 countries and regions across the world have reported more than 100,000 confirmed infections and 226 related deaths.
China reported its first imported case in September 2022 and the first domestic case in June last year.
By the end of July, the nation had reported 2,567 confirmed cases, according to the China Daily report.
Let the Truth be known. If you read VB and like VB, please be a VB Supporter and Help us deliver the Truth to one and all.
Trump repeats claim he stopped potential nuclear war between India and Pakistan
New York/Washington (PTI): US President Donald Trump has repeated his claim of resolving the India-Pakistan conflict and asserted that Islamabad's leadership credited him for saving millions of lives.
"We stopped a potential nuclear war between Pakistan and India. And the head of Pakistan, a highly respected General, he's a Field Marshal and also the Prime Minister of Pakistan, said President Trump saved 10 million lives, maybe more...,” Trump said Monday.
He made these remarks at Mar-a-Lago, Florida, flanked by Defence Secretary Pete Hegseth, Navy Secretary John Phelan, and Secretary of State Marco Rubio.
“You know, eight planes were shot down. That war was starting to rage, and he actually said the other day that President Trump saved 10 million lives, maybe more. So we solved all these wars. The only one I haven't solved yet is Russia, Ukraine,” he said.
ALSO READ: Man murders colleague, dumps body in water tank in Palghar; held
Since May 10, when Trump announced on social media that India and Pakistan had agreed to a “full and immediate” ceasefire after a “long night” of talks mediated by Washington, he has repeated his claim over 60 times that he “helped settle” the tensions between the two neighbours.
New Delhi has consistently denied any third-party intervention.
India launched Operation Sindoor on May 7, targeting terror infrastructure in Pakistan and Pakistan-occupied Kashmir in retaliation for the April 22 Pahalgam attack that killed 26 civilians.
India and Pakistan reached an understanding on May 10 to end the conflict after four days of intense cross-border drone and missile strikes.
